(via Thenewswire.ca)
Ottawa, ON / TheNewswire / March 29 2016 - Avivagen Inc. (TSXV: VIV, OTC Pink: CHEXF), a life sciences company commercializing products to replace the antibiotics used in livestock feeds, announces that it has retained the services of Renmark Financial Communications Inc. for investor relations activities.
Cameron Groome, President and Chief Executive Officer of Avivagen Inc. noted "we are pleased to announce that we have selected Renmark to reinforce Avivagen's profile in the financial community and enhance the visibility of our product portfolio. We selected Renmark because its standards and methodologies fit with the message we wish to communicate to the investing public".
In consideration of the services to be provided, Avivagen Inc. has agreed to pay a monthly retainer of Canadian $4,000 starting April 1st, 2016 to Renmark Financial Communications Inc.
Renmark Financial Communications does not have any interest, directly or indirectly, in Avivagen Inc., or its securities, or any right or known intention to acquire such an interest.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV" and on OTC Pink as "CHEXF." The Company is developing scientifically-proven products for replacing antibiotics in livestock feeds and to benefit human and animal health. Its target markets include enhancing productivity and health in livestock, companion animal quality-of-life, and maintaining optimal health in humans.
Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.
About Avivagen's Technology
Avivagen's proprietary and patented technology derives from its discovery that carotenoid oxidation produces oxygen copolymer products that have beneficial immunological properties. Avivagen's commercial-stage application of its inventions is fully oxidized beta-carotene ("OxBC"), OxC-beta(TM) Technology ("OxC-beta"). Avivagen has discovered that OxC-beta can help an animal's own systems to maintain and enhance health by supporting immune function and calming excess inflammation. Avivagen is developing OxC-beta to replace the antibiotics used for disease prevention and growth promotion in livestock feeds, to enhance quality of life of companion animals and to help maintain optimal health in humans. Avivagen's commercial products are OxC-beta(TM) Livestock (Kingdom of Thailand), Vivamune(TM) Vital Health3 Chews (U.S.) and Oximunol(TM) Chewable Tablets (U.S.).
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "aim", "anticipate", "appear", "believe", "consider", "could", "estimate", "expect", "if", "intend", "goal", "hope", "likely", "may", "plan", "possibly", "potentially", "pursue", "seem", "should", "whether", "will", "would" and similar expressions. Statements about uses of the technologies described in this news release, including their importance to animal or human health, their novelty, safety, efficacy or affordability, or management's opinions, are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: its ability to continue as a going concern. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome, CEO & President
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164 Website: www.avivagen.com
Renmark Financial Communications Inc.
Bettina Filippone: bfilippone@renmarkfinancial.com
Laura Welsh: lwelsh@renmarkfinancial.com
Telephone: 416-644-2020 or 514-939-3989
Website: www.renmarkfinancial.com
Copyright (C) 2016 Avivagen Inc.
OxC-beta(TM), Vivamune(TM) and Oximunol(TM) are trademarks of Avivagen Inc.
Copyright (c) 2016 TheNewswire - All rights reserved.